Zortix
Sign in
What finance podcasts are saying about

BMY

In-depth coverage
1
Mentions · 7d
2
Mentions · 30d
4
Mentions · 90d
5
Episodes
Latest attributed ideas · most recent first
3 AUGYESTERDAYMOTLEY FOOL MONEY · 2:30
AstraZeneca-Bristol Myers merger skepticism
“The speakers argued that a potential AstraZeneca-Bristol Myers Squibb merger is a questionable, size-for-size's-sake deal that could dilute AstraZeneca's growth and face significant antitrust hurdles.”
In depth · 4/5Verify in source →
23 JUL2W AGOCNBC FAST MONEY · 07:30
Capital rotates into large-cap pharma and biotechs
“The panel presented large-cap pharmaceutical and biotech stocks as primary beneficiaries of rotation out of volatile tech and AI names.”
In depth · 4/5Verify in source →
30 JUN30 JUNCNBC FAST MONEY · 03:40
AI drug discovery tools boost pharma efficiency
“Anthropic's new Claude Science platform was framed as an AI tool to accelerate drug discovery and improve R&D efficiency for major pharmaceutical companies.”
In depth · 4/5Verify in source →
8 JUN8 JUNMOTLEY FOOL MONEY · 10:35
Bristol-Myers' growth portfolio eclipses legacy loss
“The argument presented is that Bristol-Myers Squibb is reaching an operational turning point where revenue from its new growth portfolio is outpacing generic revenue erosion from patent cliffs.”
In depth · 4/5Verify in source →
19 DEC19 DEC 2025BARRON'S STREETWISE · 9:30
Bristol-Myers' cheap valuation with dividend
“The bull case for Bristol-Myers Squibb: its status as a 'have-not' in the drug industry has created a cheap valuation with a high, sustainable dividend and an underappreciated pipeline.”
Substantive discussion · 3/5Verify in source →
The weekly signal

Get a weekly digest of what podcasts said about your watchlist.

Pick a few tickers. Once a week we send the most-discussed ideas across finance podcasts, attributed and linked so you can verify. No noise, no advice.

Double opt-in: we’ll email you to confirm before anything else. We store your email and chosen tickers only to send this digest. Nothing else, and we never share them.

Related tickers
GOOGLMSFTNVDAMETAAMZNAAPLMUTSLABTCORCLINTCSPY
Browse all tickers →This week’s signal →
MENTIONS & DEPTH REFLECT PODCAST DISCUSSION VOLUME · NOT A RATING, FORECAST, OR RECOMMENDATION